TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Interest Expense

Cost of servicing the company's debt during the period.

TG Therapeutics, Inc.NASDAQ: TGTX

Interest Expense · Q3 FY2026 · quarter ended Sep 2026

Interest expense growth accelerates

Q3 FY2026 interest expense of $15.82M rose 135.4% year over year, ahead of the +70.9% change in trailing-twelve-month interest expense. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +37.9% a year.

Context

  • Interest expense amounted to 4.3% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +135.4% holds above the trailing-twelve-month pace of +70.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$15.82M-4.5% QoQ
Last fiscal yearDec 2025
$26.73M+11.2% YoY
LTMSep 2026
$46.59M+70.9% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+135.4%——
1 year+11.2%——
3-year CAGR+37.9%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
26.73M USD
Year-over-year change
+11.2%
4-year CAGR
+47.6%

Interest Expense vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +70.9% is the 2nd highest of 5, against a peer median of -9.3%.
  • Interest expense amounts to 5.2% of revenue for TGTX, versus a peer median of 15.8%.
TGTX Competitors
Interest Expense for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$269.28M USD—+42.7%6.5%
ADCTADC Therapeutics S.A.LTM Mar 2026$51.75M USD+3.6%+12.0%65.4%
TGTXTG Therapeutics, Inc.LTM Sep 2026$46.59M USD+70.9%+37.9%5.2%
XNCRXencor, Inc.LTM Jun 2026$27.07M USD-47.6%—25.8%
MGNXMacroGenics, Inc.LTM Mar 2026$13.31M USD+13616.5%—8.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$1.78M USD———
ADAGAdagene Inc.LTM Jun 2024$974.16K USD—-12.6%119.4%
IPHAInnate Pharma S.A.FY2025€440K EUR-22.3%+15.2%15.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
Peer median (excluding TGTX) —-9.3%+13.6%15.8%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.